Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: Multivariate analysis of factors affecting survival and engraftment

Bone Marrow Transplantation

Volumn 20, Issue 4, 1997, Pages 273-281

  Klumpp, T R ^a,b   Goldberg, S L ^a   Magdalinski, A J ^a   Mangan, K F ^a  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Bone marrow transplantation; Breast cancer; Carboplatin; Cyclophosphamide; Etoposide; Hematopoietic stem cell transplantation

Indexed keywords

ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLONY FORMING UNIT GM; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030792683     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700882     Document Type: Article

References (52)

1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. in: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 4th edn. Lipincott: Philadelphia, 1993, pp 1264-1332.
2. Aisner J, Cirrincione C, Perloff M et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol 1995; 13: 1443-1452.
3. Calabresi F, Di Lauro L, Marolla P et al. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study. Semin Oncol 1991; 18: 66-72.
4. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-1252.
5. Gelmon KA, O'Reilly SE, Tolcher AW et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185-1191.
6. Muss HB, Case LD, Richards F II et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. New Engl J Med 1991; 325: 1342-1348.
7. Tannock IF, Boyd NF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-1387.
8. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. New Engl J Med 1995; 332: 901-906.
9. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New Engl J Med 1994; 330: 1253-1259.
10. Antman K, Gale RP. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med 1988; 108: 570-574.
11. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
12. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
13. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
14. Bowers C, Adkins D, Dunphy F et al. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Bone Marrow Transplant 1993; 12: 525-530.
15. Broun ER, Sridhara R, Sledge GW et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13: 2050-2055.
16. Dunphy FR, Spitzer G, Rossiter Fornoff JE et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157-2167.
17. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
18. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
19. Fields KK, Perkins JP, Hiemenz JW et al. Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. Surg Oncol 1993; 2: 87-95.
20. Ghalie R, Williams SF, Valentino LA et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995; 1: 40-46.
21. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-1164.
22. Kennedy MJ, Vogelsang GB, Beveridge RA et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478-484.
23. Klumpp TR, Mangan KF, Glenn LD et al. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337-339.
24. Kritz A, Crown JP, Motzer RJ et al. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. Cancer 1993; 71: 2515-2521.
25. Patrone F, Ballestrero A, Ferrando F et al. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 1995; 13: 840-846.
26. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
27. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
28. Shpall EJ, Jones RB, Bast RC et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991; 9: 85-93.
29. Somlo G, Doroshow JH, Forman SJ et al. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 1994; 73: 125-134.
30. Stadtmauer EA, Hodi FS, Sickles C et al. High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer. Prog Clin Biol Res 1994; 389: 487-495.
31. Spitzer TR, Cirenza E, McAfee S et al. Phase I-II trial of high-dose cyclophosphamide, carboplatin, and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15: 537-542.
32. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
33. Vaughan WP, Reed EC, Edwards B et al. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619-624.
34. Durand RF, Goldie JH. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep 1987; 71: 673-679.
35. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-instutional study. J Clin Oncol 1993; 11: 598-606.
36. Loehrer PJ, Ansari R, Gonin R et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13: 2594-2599.
37. Cocconi G, Tonato M, Di Costanzo F et al. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research. Eur J Cancer Clin Oncol 1986; 22: 761-764.
38. Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990; 8: 327-334.
39. Cocconi G, Bisagni G, Bacchi M et al. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991; 9: 664-669.
40. Klumpp TR, Mangan KF, Glenn LD et al. Phase I/II study of high-dose cyclophosphamide, etoposide, and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12: 337-345.
41. Ravdin PM, Osborne CK. Breast cancer. In: Macdonald JS, Haller DG, Mayer RJ (eds). Manual of Oncologic Therapeutics, 3rd edn. Lippincott: Philadelphia, 1995, pp 153-161.
42. Mangan K, Mullaney M, Klumpp T et al. Mobilization of peripheral blood stem cells by subcutaneous injections of yest-derived granulocyte macrophage colony stimulating factor: a phase I-II study. Stem Cells 1993; 11: 445-454.
43. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
44. The LIFETEST Procedure. In: SAS/STAT User's Guide, Version 6, 4th edn, vol. 2. SAS Institute, Inc: Cary, NC, 1990, pp 1027-1069.
45. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
46. Schenkein DP, Dixon P, Desforges JF et al. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation with posttransplant Interferon alfa-2b for patients with lymphoma and Hodgkin's disease. J Clin Oncol 1994; 12: 2423-2431.
47. Tenny CM, Jacobs SA, Stoller RG et al. Ablative chemotherapy with cyclophosphamide, etoposide, cis-platinum or carboplatinum and autologous bone marrow rescue in patients with recurrent breast cancer. Proc Am Soc Clin Oncol 1990; 9: 46 (Abstr. 175).
48. Motzer RJ, Mazumdar M, Bosl GJ et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 14: 1098-1105.
49. Ascensao JL, Miller KB, Schenkein D et al. A new regimen for relapsed lymphomas: high-dose carboplatin, VP-16, and cyclophosphamide with hemopoietic rescue. Proc Am Soc Clin Oncol 1991; 10: 284 (Abstr. 991).
50. Shea TC, Storniolo AM, Mason JR el al. A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol 1992; 19: 139-144.
51. Saez RA, Slease RB, Strnad C et al. High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study. Bone Marrow Transplant 1995; 16: 507-514.
52. Ibrahim A, Zambon E, Bourhis JH et al. High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. Eur J Cancer 1993; 29A: 1398-1403.